A trial of VIS649, an monoclonal antibody, for the treatment of IgA nephropathy.
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2017
At a glance
- Drugs VIS 649 (Primary)
- Indications IgA nephropathy
- Focus Adverse reactions
- Sponsors Visterra
- 17 Nov 2017 Status changed from not stated to planning.
- 16 Nov 2017 New trial record
- 18 Oct 2017 According to Visterra media release, company plans to initiate the trial in 2018.